A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
Original languageEnglish (US)
U.S. patent number11046647
Filing date2/26/20
StatePublished - Jun 29 2021


Dive into the research topics of 'Activators of the unfolded protein response'. Together they form a unique fingerprint.

Cite this